Hansoh Pharmaceutical Group Company Limited (HK:3692)
:3692
Want to see HK:3692 full AI Analyst Report?
3692 Stock Chart & Stats
HK$39.76
HK$0.26(1.60%)
At close: 4:00 PM EST
HK$39.76
HK$0.26(1.60%)
Day’s Range― - ―
52-Week RangeHK$26.80 - HK$44.22
Previous CloseN/A
Volume4.63M
Average Volume (3M)9.67M
Market Cap
HK$173.19B
Enterprise ValueHK$161.34B
Total Cash (Recent Filing)HK$31.58B
Total Debt (Recent Filing)HK$105.14M
Price to Earnings (P/E)26.7
Beta0.53
Next Earnings
Aug 20, 2026EPS Estimate
0.56Next Dividend Ex-DateN/A
Dividend Yield0.97%
Share Statistics
EPS (TTM)0.93
Shares Outstanding6,064,150,000
10 Day Avg. Volume6,926,281
30 Day Avg. Volume9,666,344
Financial Highlights & Ratios
PEG Ratio1.36
Price to Book (P/B)5.48
Price to Sales (P/S)12.90
P/FCF Ratio31.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$46.65Price Target Upside17.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)0.99
Revenue Forecast (FY)HK$16.93B
Bulls Say, Bears Say
Bulls Say
High ProfitabilityVery high and consistent margins indicate strong pricing power and a portfolio of differentiated branded drugs. Sustained gross margins near 90% and healthy net margins support durable cash generation, enabling reinvestment in R&D and commercial expansion over the medium term.
Strong Cash GenerationOperating cash flow comfortably exceeding net income and free cash flow tracking earnings imply high earnings quality and internal funding capacity. Reliable cash conversion supports capex, R&D funding, dividends or buybacks without heavy external financing over several years.
Conservative Balance SheetExtremely low leverage and a large equity base give flexibility to invest, M&A or withstand sector shocks. Healthy ROE (~15%) shows efficient capital use. The conservative capital structure reduces refinancing risk and preserves strategic optionality across economic cycles.
Bears Say
Cash Conversion VolatilityWhile 2025 cash metrics are strong, historical swings (notably weak coverage in 2023) show cash conversion is inconsistent. Persistent volatility raises execution risk for funding R&D and working capital needs, complicating planning and reducing predictability of free cash flow.
Historical Leverage VariabilityPrior periods of materially higher leverage indicate the company has shifted capital structure before, which may recur if financing needs or strategic moves arise. Such variability can increase risk during downturns and suggests governance attention is needed on capital allocation choices.
Growth Dependence On Approvals & ReimbursementRevenue expansion relies on successful new drug approvals, physician adoption and reimbursement access in China. These external, timing-sensitive factors can delay uptake and create multi-year growth variability, making topline sustainability contingent on regulatory and payor outcomes.
Hansoh Pharmaceutical Group Company Limited News
3692 FAQ
What was Hansoh Pharmaceutical Group Company Limited’s price range in the past 12 months?
Hansoh Pharmaceutical Group Company Limited lowest stock price was HK$26.80 and its highest was HK$44.22 in the past 12 months.
What is Hansoh Pharmaceutical Group Company Limited’s market cap?
Hansoh Pharmaceutical Group Company Limited’s market cap is HK$173.19B.
When is Hansoh Pharmaceutical Group Company Limited’s upcoming earnings report date?
Hansoh Pharmaceutical Group Company Limited’s upcoming earnings report date is Aug 20, 2026 which is in 71 days.
How were Hansoh Pharmaceutical Group Company Limited’s earnings last quarter?
Hansoh Pharmaceutical Group Company Limited released its earnings results on Mar 29, 2026. The company reported HK$0.461 earnings per share for the quarter, beating the consensus estimate of HK$0.392 by HK$0.069.
Is Hansoh Pharmaceutical Group Company Limited overvalued?
According to Wall Street analysts Hansoh Pharmaceutical Group Company Limited’s price is currently Undervalued.
Does Hansoh Pharmaceutical Group Company Limited pay dividends?
Hansoh Pharmaceutical Group Company Limited pays a Quarterly dividend of HK$0.2 which represents an annual dividend yield of 0.97%. See more information on Hansoh Pharmaceutical Group Company Limited dividends here
What is Hansoh Pharmaceutical Group Company Limited’s EPS estimate?
Hansoh Pharmaceutical Group Company Limited’s EPS estimate is 0.56.
How many shares outstanding does Hansoh Pharmaceutical Group Company Limited have?
Hansoh Pharmaceutical Group Company Limited has 6,064,150,000 shares outstanding.
What happened to Hansoh Pharmaceutical Group Company Limited’s price movement after its last earnings report?
Hansoh Pharmaceutical Group Company Limited reported an EPS of HK$0.461 in its last earnings report, beating expectations of HK$0.392. Following the earnings report the stock price went down -0.648%.
Which hedge fund is a major shareholder of Hansoh Pharmaceutical Group Company Limited?
Currently, no hedge funds are holding shares in HK:3692
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Hansoh Pharmaceutical Group Company Limited Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$46.65 (17.33% Upside)
HK$46.65 (17.33% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
67.01%
12-Months-Change
Fundamentals
Return on Equity
16.71%
Trailing 12-Months
Asset Growth
31.91%
Trailing 12-Months
Company Description
Hansoh Pharmaceutical Group Company Limited
Hansoh Pharmaceutical Group Company Limited functions as an investment holding enterprise primarily engaged in the full spectrum of pharmaceutical operations—from scientific inquiry and product innovation to manufacturing and commercialization—within the People's Republic of China. Its diverse array of medications targets significant therapeutic categories, including neurological disorders, oncological conditions, anti-infective treatments, and metabolic ailments. The company's prominent offerings encompass drugs like Mailingda, prescribed for chronic myelogenous leukemia, as well as a broad portfolio that includes Ameile, Hansoh Xinfu, Pulaile, Zefei, Xinwei, Xinmei, Xintai, Tanneng, Oulanning, Ameining, Zetan, Hengjie, Hengsen, Fulaimei, Fulaidi, and Ruibote. Hansoh serves a client base predominantly consisting of pharmaceutical product distributors. Expanding its therapeutic reach, the company has established several strategic partnerships. It collaborates with Scynexis, Inc. on the advancement and market introduction of ibrexafungerp for vaginal yeast infections. Another alliance with Keros focuses on the development, production, and sales of KER-050, intended for treating cytopenias, anemia, and thrombocytopenia. Additionally, Hansoh is working with Olix Pharmaceuticals to identify and develop drug candidates for cardiovascular, metabolic, and liver-related diseases. A strategic pact with Silence Therapeutics plc is also in place to create siRNAs for three specific targets, utilizing Silence's proprietary mRNAi GOLD platform. Established in 1995, Hansoh Pharmaceutical Group Company Limited maintains its primary office in Lianyungang, People's Republic of China, and operates as a subsidiary of Stellar Infinity Company Ltd.
3692 Stock 12 Month Forecast
Average Price Target
HK$46.65
▲(17.33% Upside)
Technical Analysis
HUTCHMED (China)
―
China Medical System Holdings
―
Livzon Pharmaceutical Group
―
Shanghai Fosun Pharmaceutical (Group) Co
―
China Resources Pharmaceutical Group Ltd.
―
Options Prices
Currently, No data available
---